{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:57Z","timestamp":1777984317473,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European and Developing Countries Clinical Trials Partnership (EDCTP)-2","award":["RIA2017S-2012"],"award-info":[{"award-number":["RIA2017S-2012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09466-0","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:46:33Z","timestamp":1769737593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)"],"prefix":"10.1186","volume":"27","author":[{"given":"Hamu J.","family":"Mlyuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonce","family":"Liyoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Nyaulingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Mpolya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar L.","family":"Kaswaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadija","family":"Semvua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samwel","family":"Lwambura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim D.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilber","family":"Sabiiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayode R.","family":"Adegbite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marriot","family":"Nliwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Khosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mbelele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benno","family":"Mbeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kidola","family":"Jeremiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stellah G.","family":"Mpagama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SimpliciTB Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"12","key":"9466_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226507","volume":"14","author":"NM Chaves Torres","year":"2019","unstructured":"Chaves Torres NM, Quijano Rodr\u00edguez JJ, Porras Andrade PS, Arriaga MB, Netto EM. Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis. PLoS One. 2019;14(12):e0226507.","journal-title":"PLoS One"},{"key":"9466_CR2","volume-title":"WHO end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015","author":"World Health Organisation","year":"2021","unstructured":"World Health Organisation. WHO end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization; 2021."},{"key":"9466_CR3","doi-asserted-by":"crossref","unstructured":"Karumbi J, Garner P. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;5:CD003343.","DOI":"10.1002\/14651858.CD003343.pub4"},{"key":"9466_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-253","volume":"11","author":"SD Lawn","year":"2013","unstructured":"Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med. 2013;11:25.","journal-title":"BMC Med"},{"key":"9466_CR5","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","volume":"106","author":"LJ Abu-Raddad","year":"2009","unstructured":"Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr., Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009;106:13980\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"9466_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577\u201387.","journal-title":"N Engl J Med"},{"issue":"17","key":"9466_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med. 2014;371(17):1599\u2013608.","journal-title":"N Engl J Med"},{"issue":"8","key":"9466_CR8","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","volume":"48","author":"R Jayaram","year":"2004","unstructured":"Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2004;48(8):2951\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"9466_CR9","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1128\/AAC.00912-12","volume":"56","author":"IM Rosenthal","year":"2012","unstructured":"Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012;56(8):4331\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"9466_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","volume":"187","author":"JEM De Steenwinkel","year":"2013","unstructured":"De Steenwinkel JEM, Aarnoutse RE, De Knegt GJ, Ten Kate MT, Teulen M, Verbrugh HA, et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med. 2013;187(10):1127\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"9466_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy026","volume":"67","author":"EM Svennson","year":"2018","unstructured":"Svennson EM, Svennson RJ, te Brake LHM, Boeree MJ, Heinrich N, Konsten S, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67(1):34\u201341.","journal-title":"Clin Infect Dis"},{"key":"9466_CR12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191:1058\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"9466_CR13","doi-asserted-by":"crossref","unstructured":"Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ, PanACEA Consortium. Increased bactericidal activity but dose-limiting intolerability at 50 mg\/kg rifampicin. Eur Resp J. 2021; 58(1):1\u201311.","DOI":"10.1183\/13993003.00955-2020"},{"key":"9466_CR14","doi-asserted-by":"crossref","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya EN, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafaya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, Plemper van Balen G, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA Consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17:39\u201349.","DOI":"10.1016\/S1473-3099(16)30274-2"},{"issue":"3","key":"9466_CR15","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1093\/cid\/ciac585","volume":"76","author":"C Sekaggya-Wiltshire","year":"2023","unstructured":"Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, et al. Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with tuberculosis and human immunodeficiency virus receiving high-dose rifampicin. Clin Infect Dis. 2023;76(3):e910\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"9466_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.634","volume":"102","author":"RM Savic","year":"2017","unstructured":"Savic RM, Weiner M, Mackenzie WR, Engle M, Whitworth WC, Johnson JL, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017;102(2):321\u201331.","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"9466_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705\u201318.","journal-title":"N Engl J Med"},{"key":"9466_CR18","volume-title":"WHO consolidated guidelines on tuberculosis module 4: drug-susceptible tuberculosis treatment","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis module 4: drug-susceptible tuberculosis treatment. World Health Organization; 2022."},{"key":"9466_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00388-2022","author":"L Guglielmetti","year":"2022","unstructured":"Guglielmetti L, G\u00fcnther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL, et al. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.00388-2022.","journal-title":"Eur Respir J"},{"issue":"4","key":"9466_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1473-3099(13)70034-3","volume":"13","author":"RS Wallis","year":"2013","unstructured":"Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, et al. Tuberculosis biomarker discovery: developments, needs and challenges. Lancet Infect Dis. 2013;13(4):362\u201372.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"9466_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/thoraxjnl-2019-214238","volume":"75","author":"W Sabiiti","year":"2020","unstructured":"Sabiiti W, Azam K, Farmer ECHW, Kuchaka D, Mtafya B, Bowness R, et al. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay. Thorax. 2020;75(7):606\u20138.","journal-title":"Thorax"},{"key":"9466_CR22","unstructured":"WHO global lists of high burden countries for TB, multidrug\/rifampicin-resistant TB (MDR\/RR-TB) and TB\/HIV, 2021\u20132025. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"9466_CR23","unstructured":"World Health Organisation Global Tuberculosis Report. 2021."},{"key":"9466_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102857","volume":"77","author":"KA Haigh","year":"2024","unstructured":"Haigh KA, Twabi HH, Boloko L, Namale PE, Lutje V, Nevitt S, et al. Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis. EClinicalMedicine. 2024;77:102857.","journal-title":"EClinicalMedicine"},{"key":"9466_CR25","doi-asserted-by":"crossref","unstructured":"Arbiv OA, Holmes T, Kim MJ, Yan M, Romanowski K, Brode SK, Burman WJ, Menzies D, Johnston J. Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2025;81(1):119\u201328.","DOI":"10.1093\/cid\/ciaf004"},{"key":"9466_CR26","doi-asserted-by":"crossref","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, eeum S, Shim T, Barry III CE, Zimmerman M, Dartois V, Savic RM. Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLOS Med. 2019;16(4):e1002773.","DOI":"10.1371\/journal.pmed.1002773"},{"issue":"2","key":"9466_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","volume":"12","author":"PM Tulkens","year":"2012","unstructured":"Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D. 2012;12(2):71\u2013100.","journal-title":"Drugs R D"},{"issue":"4","key":"9466_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5588\/ijtld.20.0513","volume":"25","author":"CD Tweed","year":"2021","unstructured":"Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, Ban AYL, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305\u201314.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"9466_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):37.","journal-title":"J Biomed Inform"},{"key":"9466_CR30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Published 2017."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09466-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:15:33Z","timestamp":1772018133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9466"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09466-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7238156\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approvals for this trial have been sought from all sites\u2019 local and\/or national ethical committees; Tanzania (KIDH and National Institute of Medical Research (NIMR)), Gabon (CERMEL and National Research Ethics Committee), Malawi (KUHeS Ethical Committee), and Mozambique (INS Institutional Review Board and Comit\u00e9 Nacional de Bio\u00e9tica para Sa\u00fade). Also, the trial has received clinical trial authorization from medicines regulatory authorities in all participating countries, namely; Tanzania Medicines and Medical Devices Authority (TMDA), Malawi Pharmacy and Medicines Regulatory Authority (PMRA), Gabon Directorate of Medicines and Pharmacy (DMP) and Mozambique Autoridade Nacional Regulatoria de Medicamentos (ANARME).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Written informed consent will be obtained from all participants prior to enrolment. Original ICFs will be kept in regulatory binders at each site and will be available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"None of the authors has any competing interest to declare. In addition, the funder has no influence on design, implementation and reporting of this clinical trial research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"182"}}